annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 52F Absence of correlation between the molecular subtype of COL1A1-PDGFB
fusion gene and the clinico-histopathological features of
dermatofibrosarcoma protuberans: Analysis of 35 novel cases and review of
137 cases from the literature. (Abstract #10071)
D. Giacchero, G. Maire, P. Nuin, J. Coindre, J. P. Lacour, F. Pedeutour
Brd. 52G Nonstandard dosing in gastrointestinal stromal tumors: A registry
observation. (Abstract #10072)
P. W. Pisters, M. von Mehren, E. Stealey, L. A. Sirulnik, J. C. Trent
Brd. 52H Imaging-guided core needle biopsies (CNB) compared to surgical biopsies
(SB) for soft tissue tumors: A cost-effectiveness analysis. (Abstract #10073)
S. Taieb, Y. Robin, M. Morel, F. Watelle, L. Vanseymortier, N. Penel
Brd. 53A First-line chemotherapy for malignant peripheral nerve sheath tumor
(MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as
a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma
Group (STBSG) study. (Abstract #10074)
J. R. Kroep, M. Ouali, H. Gelderblom, A. Le Cesne, T. J. Dekker, M. M. Van
Glabbeke, P. Hohenberger, P. C. Hogendoorn
Brd. 53B First report of outcomes with neoadjuvant chemoradiotherapy (NCR) using
weekly intravenous (IV) cisplatin with radiation (NCWR) for treatment of
stage II and III extremity soft tissue sarcoma (STS). (Abstract #10075)
K. K. Curtis, J. B. Ashman, C. P. Beauchamp, M. D. Callister, M. W. Dopp,
A. C. Dueck, L. L. Gunderson, T. R. Fitch
Brd. 53F Antitumor activity of pemetrexed (Pem) in second-line advanced/metastatic
osteosarcomas: A multicenter phase II study. (Abstract #10076)
N. Bin Bui, G. Egerer, S. Ferrari, A. Comandone, A. Cioffi, H. Rassam, A. Michel,
S. Ameryckx, S. Weitckus, F. Duffaud
Brd. 53G Evaluation of quality of life in patients treated with resection and
reconstruction of the upper or lower limb for bone sarcomas. (Abstract
#10077)
P. Ruggieri, M. Montalti, E. Pala, G. Guerra, T. Calabrò, A. Angelini, N. Fabbri,
S. Ferrari, P. Picci, M. Mercuri
Brd. 53H Prognostic significance of proliferation markers and telomerase activity in
gastrointestinal stromal tumors. (Abstract #10078)
A. Augustinakova, H. Brizova, I. Hilska, M. Kalinova, R. Kodet
Brd. 54A Effect of adjuvant radiotherapy on survival in localized limb or trunk wall
well-differentiated liposarcoma (WDLPS). (Abstract #10079)
A. Duret, E. Stoeckle, S. Bonvalot, A. Italiano, S. Piperno-Neumann, G. Kantor,
C. le Pechoux, L. Guillou, J. Coindre, J. Blay
Brd. 54B Efficacy of neoadjuvant doxorubicin and ifosfamide (AI) in myxoid /round cell
liposarcoma (MRCL): The M. D. Anderson Cancer Center experience
(MDACC). (Abstract #10080)
D. Katz, P. Boonsirikamchai, R. S. Benjamin, S. Patel, J. A. Ludwig, J. C. Trent,
L. Xiao, V. Ravi, H. Choi, D. M. Araujo
Brd. 54F Assessment of early response to imatinib 800 mg after 400 mg progression
by 18 f-fluorodeoxyglucose positron emission tomography in patients with
metastatic gastrointestinal stromal tumor. (Abstract #10081)
A. Rodriguez Espíndola, M. Chacon, M. Eleta, E. Roca , G Mendez , S. Rojo,
C. Puparelli, R Chacon
Brd. 54G Effect of radiation therapy on survival of patients with surgically resected
retroperitoneal sarcoma: A population-based matched pair study.
(Abstract #10082)
A. Choi, J. Barnholtz-Sloan, J. Kim
Brd. 54H Sunitinib as the second-line therapy for advanced GISTs after failure of
imatinib in Korean patients. (Abstract #10083)
M. Ryu, D. Yoon, B. Ryoo, M. Beck, D. Choi, Y. Cho, J. Lee, H. Chang, T. Kim,
Y. Kang
283
SUNDAY